Pl find enclosed unaudited financial results along with LRR for quarter ended 30th June, 2026
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 14 Aug 2026, 01:53 PM IST · BSE ID: 20e45b3e-1bfa-43f9-b4c2-8668b09535e7
View Original BSE Filing (PDF)
💡
In Simple Terms
Alkem Laboratories has released its financial results for the first three months of the fiscal year 2027.
🤖 AI Summary
- Alkem Laboratories' Board approved Consolidated Unaudited Financial Results for the quarter ended June 30, 2026.
- Revenue from Operations reached ₹37,401.5 Million for the quarter, up from ₹33,711.4 Million YoY.
- Profit before tax for Q1 FY27 was ₹7,719.9 Million, compared to ₹7,710.1 Million in Q1 FY26.
- Total Tax Expense for the quarter ended June 30, 2026, stood at ₹2,505.0 Million.
- Consolidated Profit after tax was ₹5,209.8 Million for the quarter.
- The Board meeting commenced at 11:00 a.m. and concluded at 01:40 p.m. on August 14, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Revenue from Operations
37,401.5 Million
10.95%
Consolidated Profit before tax
7,719.9 Million
0.13%
Consolidated Profit after tax
5,209.8 Million
4.99%
Total Tax Expense
2,505.0 Million
144.91%
🏢 How This Affects the Company
The company reported a 10.95% increase in Consolidated Revenue from Operations, reaching ₹37,401.5 Million for the quarter ended June 30, 2026, indicating continued business activity.
Consolidated Profit after tax for the quarter was ₹5,209.8 Million, reflecting the company's profitability in the initial quarter of FY27.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results disclosure.
👤
Who Is Affected
All existing shareholders are affected by these financial results, which confirm the company's performance for the quarter ended June 30, 2026.
🔍
Management Signal
The approval and disclosure of unaudited financial results signal management's adherence to regulatory compliance and transparent reporting.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 financial results — check for sustained revenue growth and cost management.
Any further exceptional items disclosures — monitor their impact on profitability.
Review of subsidiary performance, especially those not audited by primary auditors.
MEDIUM RISK
Increased finance costs and other expenses, alongside a significant jump in tax expense, merit closer monitoring.
💡 Investor Takeaway
Alkem Laboratories reported consolidated Revenue from Operations of ₹37,401.5 Million for Q1 FY27, a 10.95% increase from ₹33,711.4 Million in Q1 FY26. Consolidated Profit after tax stood at ₹5,209.8 Million, up from ₹4,961.8 Million YoY.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated Revenue from Operations increased by 10.95% to ₹37,401.5 Million for Q1 FY27 from ₹33,711.4 Million in Q1 FY26.
- Profit before tax for Q1 FY27 was ₹7,719.9 Million, marginally higher than ₹7,710.1 Million in Q1 FY26.
⚠️ Concerns
- Other expenses increased by 25.57% to ₹9,639.3 Million in Q1 FY27 from ₹7,676.8 Million in Q1 FY26.
- Finance costs increased by 56.55% to ₹466.2 Million in Q1 FY27 from ₹297.8 Million in Q1 FY26.
📅 Company Track Record
Alkem Laboratories reported record FY26 EBITDA of ₹30,052 million and 14.6% Q4 FY26 revenue growth in a filing on May 28, 2026. The company also approved FY26 results and recommended a ₹10 final dividend at that time.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Alkem Laboratories' consolidated revenue from operations for Q1 FY27?
Alkem Laboratories reported a consolidated Revenue from Operations of ₹37,401.5 Million for the quarter ended June 30, 2026, an increase from ₹33,711.4 Million in the prior year.
What was Alkem Laboratories' consolidated profit after tax for the quarter ended June 30, 2026?
The consolidated Profit after tax for Alkem Laboratories was ₹5,209.8 Million for the quarter ended June 30, 2026.
How did Alkem Laboratories' total tax expense change in Q1 FY27?
Alkem Laboratories' Total Tax Expense increased to ₹2,505.0 Million for Q1 FY27, up from ₹1,026.9 Million in the corresponding quarter of the previous year.
What was the profit before tax for Alkem Laboratories in Q1 FY27?
Alkem Laboratories' consolidated Profit before tax was ₹7,719.9 Million for the quarter ended June 30, 2026.
Questions based on this BSE filing only. For information purposes.